6 hrs ago | AME Info
The Saudi Food and Drug Authority has said Lifescan, a Johnson and Johnson company, has withdrawn and replaced OneTouch Verio IQ and OneTouch Verio Pro home use devices for testing blood sugar level because they give a wrong reading for the glucose level in the blood, Saudi Gazette has reported.
18 hrs ago | Examiner.com
Over the past several months, since the Federal Reserve has been purposefully printing more than $85 billion per month to prime markets, the primary stock exchanges have all reached new highs, with little risk to push equities down against the trend.
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth With More than 10 Potential New Product Filings by 2017 announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson & Johnson said it plans to seek approvals for 11 new drugs by 2017, including a treatment for patients with depression who have failed to benefit from standard medications.
Johnson & Johnson : We're Creaming Medivation, Inc. , Boehringer Ingelheim Corporation , Bristol-Myers Squibb Company and Pfizer Inc.
Johnson & Johnson expects to file for Food and Drug Administration approval of more than 10 new drugs over the next four years, the drug maker said Thursday.
Shares of Johnson & Johnson have been in a solid uptrend throughout 2013. As shown in the chart below, the stock looks extended now, so investors should wait for a pullback.
Health-care giant Johnson & Johnson plans to seek approval for 10 new treatments to combat cancer, Hepatitis C, schizophrenia and influenza over the next four years, the company said Thursday.
BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.
Johnson & Johnson said its pharmaceutical unit plans to submit more than 10 new-product applications by 2017, as the health-care heavyweight hopes to build on the division's turnaround in recent years.
The firm set an "underperform" rating on the stock. A number of other firms have also recently commented on JNJ.
Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In the wake of scandals and investigations over manufacturing gaffes, countless product recalls and questionable marketing practices, Johnson & Johnson is embarking on a round of corporate soul searching.
During the second half of the 20th century, there was a small handful of blue-chip stocks that served as a "secret handshake" of sorts among those steeped in dividend investing.
Hedge funds' returns have stayed "lackluster" this year, with the $2.3 trillion industry trailing the gains of the Standard & Poor's 500 Index by about 10 percentage points, according to Goldman Sachs Group Inc.
Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.